692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not.
| Inventor | Institute |
|---|---|
| Lindy Durrant | University of Nottingham |
| SKU: | 153393 |
|---|---|
| Product description: | MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are functional glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate. |
| Conjugation: | Unconjugated |
| Isotype: | IgG3 kappa |
| Immunogen: | Colonic Adenoma membranes |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Cat. #: | 153393 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Genetics |
| Application: | FACS ; IHC |
| Target: | Lewis Y |
| Reactivity: | Human |
| Clone: | 69/229 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are Fn glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Noble et al. 2013. PLoS One. 8(2):e54892. PMID: 23408949. Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.